10:46 AM EDT, 03/13/2024 (MT Newswires) -- Silence Therapeutics ( SLN ) said Wednesday that a phase 2 study of zerlasiran in 178 subjects with high lipoprotein(a) met its primary endpoint and showed a "highly significant" reduction in lipoprotein(a) from baseline, compared with placebo to 36 weeks.

Lipoprotein(a) is key a genetic risk factor for cardiovascular disease, the company said.

The study showed a median percentage reduction in lipoprotein(a) of at least 90% for two doses at week 36, while no new safety concerns were identified during the period, Silence Therapeutics ( SLN ) said.

The company intends to report topline 48-week data from the study in Q2.

Separately, Silence Therapeutics ( SLN ) reported that its 2023 loss narrowed and revenue rose year-over-year.

The company's shares were down more than 10% in recent trading.

Price: 23.20, Change: -2.71, Percent Change: -10.44